126 results about "Drug uptake" patented technology

A composite formulation has been developed for selective, high efficacy delivery to specific regions of the mouth and gastrointestinal tract. The formulation is typically in the form of a tablet or capsule, which may include microparticles or beads. The formulation uses bioadhesive and controlled release elements to direct release to specific regions, where the drug is absorbed in enhanced amounts relative to the formulation in the absence of the bioadhesive and / or controlled release elements. This is demonstrated by an example showing delivery of gabapentin with a greater area under the curve (“AUC”) relative to the FDA reference immediate release drug, i.e., the AUC of the composite bioadhesive formulation is greater than 100% of the AUC of the immediate release drug. In the preferred embodiments, the formulation includes drug to be delivered, controlled release elements, and one or more bioadhesive elements. The bioadhesive polymer may be either dispersed in the matrix of the tablet or applied as a direct compressed coating to the solid oral dosage form. The controlled release elements are selected to determine the site of release. The bioadhesive components are selected to provide retention of the formulation at the desired site of uptake and administration. By selecting for both release and retention at a specific site, typically based on time of transit through the gastrointestinal tract, one obtains enhanced efficacy of uptake of the drug. This is particularly useful for drugs with narrow windows of absorption, and drugs with poor solubility such as the BCE class III and class IV drugs.

A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.

A composition including a surfactant and at least one alkyl glycoside and / or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.

The inhalation therapy assembly and method of use described herein increases the efficiency of metered dose inhalers by allowing delivery of the doses to a collapsible reservoir which can be manually pumped, ensuring that medicants contained therein are properly and completely delivered to the patient. Terminal and proximal valves of the one-way diaphragm type allow flow of the aerosol medicants while preventing improper expulsion. An exhalation valve is adjustable to ensure the patient exhales suitably to permit proper medicant absorption. A conventional metered dosage inhaler having an approved FDA canister provides proper dosage to the patient and is joined to the collapsible reservoir by a connector having a plurality of apertures for receiving the MDI and an accessory T-fitting.

The present invention in one aspect provides methods of enhancing uptake of a therapeutic agent in a target tissue as well as methods of treating a disease (such as cancer) or enhancing effectiveness of treatment with a therapeutic agent in an individual by co-administering a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane with the therapeutic agent. The present invention in another aspect provides a method of treatment or a method of selecting patients for treatment of a disease (such as cancer) with the combination of a therapeutic agent and a composition comprising nanoparticles comprising albumin and a poorly water soluble drug such as a taxane based on one or more characteristics of the target tissue that correlates or indicates the capability of getting enhanced therapeutic agent uptake as a result of the co-administration of the taxane nanoparticle composition in the target tissue (referred to as “the drug uptake capability”). Also provided are pharmaceutical compositions, article of manufacture, and kits useful for methods described herein.

The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and / or an agent which inhibits intestinal drug degradation,wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and / or the agent which inhibits intestinal drug degradation.

There is provided a powder composition for nasal administration comprising a drug having a particle size of less than 10 mum or a lyophilized drug, a water-absorbing and water-slightly soluble base material, and a water-absorbing and gel-forming base materials. The composition has excellent drug absorbability.

A bifurcated catheter having a branched distal shaft section and one or more porous or nonporous balloons, and combinations thereof, which is configured for delivery of an agent to a patient's bifurcated body lumen. Another aspect of the invention is directed to a method of delivering an agent to a patient's body lumen which facilitates maximizing the efficiency of drug uptake into the tissue at the desired site within the patient's body lumen.

The invention discloses azithromycin gel eye drops and a preparation process thereof. The eye drops are prepared from a main medicine, namely azithromycin and excipients such as an adhesive, a gel matrix, an isotonic regulator, a preservative, an antioxidant, a buffering agent and the like. The adhesive, namely polycarbophil in the eye drops can increase the biological adhesion of the eye drops, so that the detention time of medicines in eyes is further prolonged. The invention provides a practical, convenient and reliable ophthalmic preparation for treating bacterial conjunctivitis, and solves the problems that the detention time of medicines in an eye drop formulation in the eyes is short, the medicines are not easy to absorb, the bioavailability is low and the like.

The invention discloses an acid-responsive nanometer micelle for drug loading, a preparation method and an application thereof. The nano-micelles were self-assembled from hydrophilic segment polyethylene glycol (PEG) and hydrophobic segment pH-sensitive polyaspartyl diisopropylethylenediamine / di-n-butylethylenediamine (PAsp (DIP / DBA)). The nano-micelles can prolong the drug circulation time, aggregate in the tumor site, increase the local drug concentration, and respond to the micro-acid environment of the tumor tissue. As a drug carrier of stimulation response, the nano-micelles can rapidly release the loaded chemotherapeutic drug adriamycin in the tumor site, and play a significant anti-tumor effect. At the same time, the nano-micelles loaded with magnetic resonance contrast agent superparamagnetic iron oxide can be used for tumor magnetic resonance imaging and monitoring drug uptake and aggregation. This method utilizes nano-drug aggregation at tumor site and acid responsiveness ofcarrier to realize rapid drug release to improve tumor therapeutic effect, and endows nano-micellar MRI visualization function, which provides a promising innovative strategy for cancer diagnosis andtreatment, and has broad application prospects.

The invention discloses a nano-suspension for a silybin-phospholipid complex and a preparation method thereof, wherein the nano-suspension for a silybin-phospholipid complex is prepared by combining a technology of promoting medicine absorption by a phospholipid complex with a solubilizing-targeting technology of nano-suspension; the ingredients of the nano-suspension for silybin-phospholipid complex comprise a silybin-phospholipid complex, a stabilizer and water; the nano-suspension exists in the form of suspension or freeze-dried powder and prepared by combining a microprecipitation method with a high-pressure homogenization method; the method of the invention prepares a nano-suspension hard to dissolve in a medicine, without a need to pre-micronize raw material medicines, which greatly decreases energy consumption; the grain diameter distribution range of the prepared nano-grains is narrow, and the medicine highly disperses in a granular state, which increases the wettability, solubility and solution velocity of the medicine, thereby improving the oral bioavailability thereof; the technique process of the preparation method is simple and easy to realize industrial production.

The invention provides an administration composition for transferring medicaments and a preparation method and a using method thereof. The administration composition comprises a solid preparation carrying the effective dose of treatment components, a sorbefacient, a pharmaceutic adjuvant and a biologic adhesion layer containing biologic adhesion polymer, and also comprises a selectable anti-permeable or semipermeable coating layer, so that the treatment components and the sorbefacient in the preparation have unidirectional releasing capacity. The administration composition can promote the absorption of medicaments which are difficult to absorb, improves bioavailability, regulate pharmacokinetic characteristics and improve the absorption efficiency of the medicaments, has low cost and is easy to produce relatively.

The invention discloses albumin nanoparticles realizing co-delivery of an antitumor drug and an MRI (magnetic resonance imaging) contrast medium and a preparation method of the albumin nanoparticles and further provides an albumin nanoparticle vector containing the MRI contrast medium, and drug loading is realized through electrostatic adsorption and coordination between the drug and the vector as well as crosslinking of amino acid residues of the vector. The invention further discloses an optimal preparation technology of the albumin nanoparticles realizing co-delivery of the antitumor drug and the MRI contrast medium and a function of the albumin nanoparticles in diagnosis and treatment combination of tumors. According to the albumin nanoparticles realizing co-delivery of the antitumor drug and the MRI contrast medium, the drug uptake ratio of cells can be increased, and drug efflux caused by drug-resistant cells is reduced, so that drug resistance is reversed, and efficient delivery of the drug is realized; the albumin nanoparticles realizing co-delivery of the antitumor drug and the MRI contrast medium have excellent T1 weighted imaging capability and an effective means is provided for the diagnosis and treatment combination of the tumors.

The invention provides a hydrophilic antiviral drug, namely acyclovir-chitosan-stearic acid grafting, which is beneficial to the load of the drug by a target carrier material through chemical grafting by the synthesis of an acyclovir-succinic acid midbody. On the basis, by adopting the load of the antiviral drug in cells of a molecular target mark for a chitosan-stearic acid grafting micelle with high-efficiency cellular uptake and low toxicity, the drug uptake of virus cells is greatly increased, and the drug concentration of the drug molecular target mar position is increased. The acyclovir-chitosan-stearic acid grafting increases the drug uptake of virus cells, is beneficial to reducing the distribution of the drug in normal tissues or cells and reduces the toxic side effect of the drug; and the drug concentration increase of the drug molecular target mark position is beneficial to increasing the healing effect of the antiviral drug. The acyclovir-chitosan-stearic acid grafting has the chemical general formula (disclosed in the specification).

The invention discloses an abiraterone oral emulsion and a preparation method thereof. The preparation comprises an active component, a solubilizer, an emulsifier and an antioxidant; the active component is abiraterone acetate or abiraterone; and the preparation comprises, by weight, 2%-10% of abiraterone acetate or abiraterone, 20%-70% of the solubilizer, 20%-40% of the emulsifier and 0.01%-1% ofthe solubilizer. According to the invention, the drug loading capacity and the stability of the abiraterone oral emulsion are high; and the abiraterone oral emulsion can be spontaneously emulsified to form an emulsion when meeting water. And the formed emulsion is stable; the digestion influence is low; the dissolution of medicines in gastrointestinal tracts is improved; the absorption of the medicines is promoted; and the bioavailability is improved.

The invention provides an administration combination and a preparation method and a use method thereof. The administration combination comprises treatment components carrying effective doses, absorbefacient, medical auxiliary materials, and solid preparation of a bioadhesive layer containing bioadhesive polymer, and further comprises a selectable impervious or semi-permeable coating layer which ensures that the treatment components and the absorbefacient have unidirectional release capability. A unidirectional release channel with unidirectional release capability is formed through manual or laser ablation technology, and the releasing rates of the treatment components and the absorbefacient in the solid preparation are nearly the same. The invention simultaneously provides the preparation and the use methods of the administration combination. Low-dose solid preparation prepared through a non-solvent granulation process can maintain the uniformity and the stability of the treatment components. The administration combination can promote the absorption of drug difficult to be absorbed, improves the bioavailability, adjusts the pharmacodynamic feature and improves the absorption efficiency of drug, has a low price, and is relatively easy to produce.

The present invention discloses the preparation process of several kinds of externally applied dragoní»s blood preparation, including suppository, ointment and cataplasm. The externally applied dragoní»s blood preparations are prepared through treating dragoní»s blood into fine powder and conventional preparation process with the fine dragoní»s blood powder as active component and pharmaceutically acceptable carrier. The present invention has high medicine quality, high curative effect, convenient clinical application, high medicine absorption and saving in the dragoní»s blood resource.

The invention discloses a drug coated balloon dilating catheter and a process thereof. The drug coated balloon dilating catheter comprises a drug coated balloon, an outer cavity tube, an inner cavitytube and a connector. The surface of the drug coated balloon is coated with a drug coating, a release drug in the drug coating is a sirolimus derivative BA9, and a carrier of the release drug is polyethylene oxide. A manufacturing process of the drug coated balloon dilating catheter includes steps of catheter assembly and drug coating. The drug coated balloon has advantages of short tissue absorption time, high drug absorption efficiency and high drug coated balloon release rate, and high tissue safety is realized. Compared with an existing taxol drug coated balloon, the drug coated balloon has advantages of promising application prospect.

The invention discloses a dragon tree leaf / dendrobe pharmaceutical composition, and a preparation method, preparation and application thereof, belonging to the technical field of preparation of medicines. The pharmaceutical composition comprises 45-55 parts by weight of dragon tree leaf ultrafine powder and 45-55 parts by weight of dendrobe ultrafine powder. The preparation method comprises the following steps: removing impurities from dragon tree leaf and dendrobe, selecting, cleaning, airing, and drying until the water content is at most 3%; respectively pulverizing the dragon tree leaf and dendrobe with a coarse pulverizer, and passing through a 100-140-mesh screen; pulverizing the dragon tree leaf coarse powder by a jet mill to obtain the ultrafine powder with the particle size of 10-15 mu m, and pulverizing the dendrobe coarse powder by a vibromill to obtain the ultrafine powder with the particle size of 6-12 mu m; and evenly mixing the 45-55 parts by weight of dragon tree leaf ultrafine powder and the 45-55 parts by weight of dendrobe ultrafine powder. The preparation is prepared by adding pharmaceutically acceptable auxiliary materials into the pharmaceutical composition. The pharmaceutical composition can be used for preparing medicines for treating hyperplasia of mammary glands and diabetes, and has the characteristics of high bioavailability, high active component leaching speed and favorable drug absorption effect.

The invention discloses a single-chamber osmotic pump controlled release tablet containing pregabalin. The tablet comprises a single-layer piece core, a controlled release film coating layer and at least one laser hole in a controlled release film. The basic composition of the piece core includes pregabalin or salt or hydrate thereof, diluent, adhesive and lubricant, and does not include an expansible polymer. The adopted accessories are simple and economical, the tablet can be prepared through a simple direct tabletting process, and the controlled release film coating layer includes a film forming material, a pore-foaming agent and plasticizer. According to the drug release mechanism, water and a physiological medium dissolve water-soluble active components and the diluent in the piece core through the controlled release film to form trans-film osmotic pressure, the dissolved active components are released out of the piece core through the small holes in the controlled release film, the controlled release tablet can release a therapeutic drug within a certain time range at a constant drug release rate, and the influence of the stomach and intestine difference between different individuals on drug absorption can be minimized.

The invention relates to an oral drug solution formula with the function of resisting coccidium and preparation, in particular to a compound formula for improving the water solubility of a bioactivitylipophilic drug. According to the specific compound formula, the drug is mixed with one or more of organic solvents, and then mixed with various stabilizers. According to the composition formula, thedrug dosage form is made according to a making method of common drug dosage forms. After the drug dosage form made according to the method is clinically used, after the drug is diluted with water inproportion, the drug is administrated to poultry while the poultry drink water, the solubility and stability of the drug in water are improved, drug absorption is improved, and the bioavailability isimproved.

The invention belongs to the technical field of medicines, and particularly relates to a tetravalent platinum prodrug bendazac platinum, a preparation thereof, and preparation methods and applications of the prodrug and the preparation. The structural formula of the prodrug is shown in the specification. The preparation method of the prodrug comprises the following steps: (1) synthesizing hydroxyl platinum; (2) synthesizing bendazac platinum; and (3) purifying the bendazac platinum. The preparation method of the nano preparation comprises the following steps: (1) preparing a bendazac platinum solution; and (2) preparing the nano preparation by taking bovine serum albumin as a carrier. The tetravalent platinum prodrug bendazac platinum and the nano preparation thereof provided by the invention are good in water solubility, small in toxic and side effects and high in anti-tumor efficacy, can be passively targeted to a tumor site, can increase the drug uptake ability of tumor cells, and show a good anti-tumor effect, and the inhibition rates of the tetravalent platinum prodrug bendazac platinum to various tumors can be higher than 90%.

The invention relates to the technical field of medical apparatuses, and in particular discloses a multifunctional self-heating acupuncture point patch. The invention also discloses a processing method and an application of the self-heating acupuncture point patch. The self-heating acupuncture point patch comprises a heating device and a medicine layer, wherein a sticky layer is arranged on the upper surface of the heating device; the medicine layer is arranged on the lower surface of the heating device; the medicine layer sleeves inside a locator; a breathable layer covers the medicine layer and the locator; a piece of release paper is arranged on the lower side of the breathable layer; and the sticky layer is stuck with the periphery of the release paper. The problems of an existing self-heating patch that a medicine layer, at high temperature, is poor in anti-shock effect, easy for deformation, slow to take efficacy of medicines and long in treatment time can be solved. With the application of the self-heating acupuncture point patch provided by the invention, a time that medicines take effects is shortened, and meanwhile, bioavailability of the medicines is improved and absorption efficiency of the medicines is greatly improved, so that an effect of stimulating acupuncture points is enhanced; and moreover, the self-heating acupuncture point patch is broad in application scope and conducive to market popularization.